Literature DB >> 33535082

Inverse associations between cerebellar inhibition and motor impairment in spinocerebellar ataxia type 3.

Roderick P P W M Maas1, Bart P C van de Warrenburg2, Dennis J L G Schutter3.   

Abstract

BACKGROUND: Cerebellar ataxia generally results from a lesion disrupting the corticopontocerebellar or cerebellothalamocortical tract. The cerebellar inhibition (CBI) paradigm represents a dual-coil transcranial magnetic stimulation protocol that interrogates the integrity of the latter pathway. Whether CBI has clinical relevance in ataxia patients remains largely unknown because associations with pertinent disease severity measures in etiologically homogeneous cohorts have not been previously examined.
OBJECTIVE: To investigate if CBI correlates with clinical and functional indices of disease severity in individuals with spinocerebellar ataxia type 3 (SCA3).
METHODS: CBI was assessed in fourteen SCA3 patients by paired-pulse cerebellar-motor cortex (M1) stimulation using interstimulus intervals of 3, 5, and 10 ms. Correlation coefficients were determined between CBI and ataxia severity, manual dexterity, and walking speed.
RESULTS: Suppression of M1 excitability occurred 5 ms following a contralateral cerebellar conditioning stimulus in SCA3 patients, but, on average, CBI was significantly reduced as compared to a healthy control group from the literature (p < 0.001). A significant association was found between decreased CBI levels and higher Scale for the Assessment and Rating of Ataxia (SARA) scores (r = -0.62, p = 0.019). CBI was negatively correlated with axial, appendicular, and speech subscores, as well as with nine-hole peg test performance (r = -0.69, p = 0.006). No association was observed between CBI and walking speed. As expected, there were no significant clinical-neurophysiological correlations at 3 and 10 ms interstimulus intervals.
CONCLUSION: Our results provide the first neurophysiological evidence for an inverse association between cerebellothalamocortical tract integrity, as reflected by reduced levels of CBI, and ataxia severity in SCA3 patients. Longitudinal studies are required to evaluate if CBI could serve as a marker of disease progression.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebellar inhibition; Cerebellothalamocortical tract; Scale for the Assessment and Rating of Ataxia; Spinocerebellar ataxia type 3; TMS

Year:  2021        PMID: 33535082     DOI: 10.1016/j.brs.2021.01.020

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  4 in total

1.  Magnetic Resonance Imaging and Its Clinical Correlation in Spinocerebellar Ataxia Type 3: A Systematic Review.

Authors:  Kah Hui Yap; Hanani Abdul Manan; Noorazrul Yahya; Shahrul Azmin; Shahizon Azura Mohamed Mukari; Norlinah Mohamed Ibrahim
Journal:  Front Neurosci       Date:  2022-06-10       Impact factor: 5.152

2.  Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial.

Authors:  Roderick P P W M Maas; Steven Teerenstra; Ivan Toni; Thomas Klockgether; Dennis J L G Schutter; Bart P C van de Warrenburg
Journal:  Neurotherapeutics       Date:  2022-05-02       Impact factor: 6.088

3.  Effects of Repetitive Transcranial Magnetic Stimulation on Cerebellar Metabolism in Patients With Spinocerebellar Ataxia Type 3.

Authors:  Xin-Yuan Chen; Yan-Hua Lian; Xia-Hua Liu; Arif Sikandar; Meng-Cheng Li; Hao-Ling Xu; Jian-Ping Hu; Qun-Lin Chen; Shi-Rui Gan
Journal:  Front Aging Neurosci       Date:  2022-04-25       Impact factor: 5.702

4.  Differential Temporal Dynamics of Axial and Appendicular Ataxia in SCA3.

Authors:  Roderick P P W M Maas; Steven Teerenstra; Manuela Lima; Paula Pires; Luís Pereira de Almeida; Judith van Gaalen; Dagmar Timmann; Jon Infante; Chiadi Onyike; Khalaf Bushara; Heike Jacobi; Kathrin Reetz; Magda M Santana; Joana Afonso Ribeiro; Jeannette Hübener-Schmid; Jeroen J de Vries; Matthis Synofzik; Ludger Schöls; Hector Garcia-Moreno; Paola Giunti; Jennifer Faber; Thomas Klockgether; Bart P C van de Warrenburg
Journal:  Mov Disord       Date:  2022-07-08       Impact factor: 9.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.